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Abstract 
Aims: We describe the clinical characteristics, management and outcomes of patients 
hospitalised with acute heart failure (AHF) in a south western European Cardiology 
Department. We sought to identify the determinants of length of stay (LOS) and heart failure 
(HF) rehospitalisation or death during a 12-months follow-up period. 
Methods and Results: This was a retrospective cohort study including all patients admitted 
during 2010 with either a primary or secondary diagnosis of AHF. Death and readmission 
were followed through 2011.  
Amongst the 924 patients admitted, 201 (21%) had AHF, 107 (53%) of which with new-onset 
AHF. The main precipitating factors were acute coronary syndrome (ACS) (63%) and 
arrhythmia (14%). The most frequent clinical presentations were heart failure (HF) after ACS 
(63%), chronic decompensate HF (47%) and acute pulmonary oedema (21%). On admission 
73% had left ventricular ejection fraction (LVEF) < 0.50. Median LOS was 11 days and in-
hospital mortality was 5.5%. Rehospitalisation rate was 21% and 24% at six and 12 months 
respectively. All-cause mortality was 16% at 12 months. The independent predictors of re-
hospitalisation or death were HF hospitalisation during previous year (Hazard Ratio – HR – 
3.177), serum sodium < 135 mmol/L on admission (HR 1.995), atrial fibrillation (HR 1.791) 
and reduced LVEF (HR 0.518). 
Conclusions: Our patients more often presented new-onset AHF, due to an ACS, causing 
reduced LVEF. Several predictive factors of death or rehospitalisation were identified that 
may help to select high risk patients to be followed in a HF management programme after 
discharge. 
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Introduction 
Acute heart failure (AHF) is a major public health concern because of its increasing 
prevalence and associated high morbidity, mortality and costs (1-5). Despite being one of the 
most frequent reasons for hospitalisation in western countries, it has received much less 
attention than chronic heart failure (CHF) and, thus, large scale studies specifically addressing 
AHF are relatively scarce (6, 7).  
AHF is associated with a high rate of rehospitalisation but little is known regarding the most 
relevant predictive factors. Thus, it is important to develop appropriate predictive models that 
might help us to adequately stratify AHF patients and improve their management and follow-
up (8). 
Moreover, in spite of several studies conducted in Europe and the USA on the clinical 
characteristics, treatment and outcome of AHF patients, very limited information is available 
on this subject in Portugal (9). 
In the present study we describe the clinical characteristics, hospital management and 
outcomes of AHF patients admitted to a Portuguese Cardiology Department, and present a 
predictive model for readmission or death at 12-months in this population.  
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Methods  
Study description 
This is an observational hospital-based retrospective cohort study, conducted at the 
Cardiology Department of Hospital de S. João, Porto, Portugal. Demographic, clinical and 
follow-up data collection was done between the February 1st, 2011 and the December 31st, 
2011, ensuring a minimum follow-up of one year for all patients. 
Inclusion criteria 
All patients admitted to the Cardiology Department between January 1st and December 31st 
2010, were screened. Paper and computer-based clinical records from the 924 patients 
admitted to the Cardiology Department during the study period were retrieved and analysed 
by one investigator in order to find eligible patients, meeting one of the following inclusion 
criteria: 
• Primary diagnosis of AHF according to ESC criteria (3);   
• AHF secondary to another acute cardiac event (3); 
• Acute myocardial infarction classified as Killip II-IV. 
Exclusion criteria 
Programmed hospitalisations or hospitalisations in the context of cardiac surgery were 
considered exclusion criteria.  
In order to avoid duplicate records, readmissions to the hospital during the study period were 
not counted as new cases. 
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Objectives 
The primary objective of this study was to describe the clinical characteristics, hospital 
management and outcomes of patients hospitalised with AHF. 
 The secondary objectives were: 
 The comparison of patients with AHF and an ACS as the precipitating factor versus 
patients with AHF and no ACS; 
 The comparison of drug prescriptions on admission and at discharge; 
 The identification of factors associated with a longer length of stay (LOS); 
 The identification of risk factors for HF rehospitalisation or death. 
Data collection 
Patient demographics, cardiovascular risk factors, comorbidities, history of cardiac disease or 
HF as well as the results of ECG, haemodynamic, echocardiographic examinations and 
laboratory tests were collected. Data on the aetiology and the possible precipitating factors of 
AHF, drug prescriptions before and following admission, as well as data on concomitant 
medication and main diagnostic or therapeutic procedures performed during the 
hospitalisation were collected, too. The hospital LOS of patients was also recorded and in the 
case of patients transferred to another hospital or to another ward, it was recorded at the time 
of transfer. Data regarding death or rehospitalisation were obtained from the patient’s 
electronic record and did not include admissions to another hospital nor death not registered 
in the hospital administrative or clinical database. For all alive patients, the follow-up period 
finished on the December 31st, 2011. 
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Data analysis 
Categorical variables were presented as counts and percentages, and quantitative variables as 
means and standard deviation (SD) or medians and 25th percentile – 75th percentile (p25 – 
p75) as appropriate, depending on the empirical distribution of the variables.  
Subgroups of patients were compared by using chi-square test or Fisher’s exact test for 
categorical variables and T-test and Mann-Whitney rank-sum tests for symmetrical and 
asymmetrical quantitative variables, respectively. The normality of the distribution of 
quantitative variables was assessed by the Kolmogorov-Smirnov test. 
Simple and multiple linear regression models were used to analyse the variable LOS, which 
was logarithmically transformed in order to normalise its initially asymmetrical distribution. 
Survival analysis was used to analyse determinants of rehospitalisation or death. For graphs of 
survival probability, the crude effect of each variable was tested with the Log-rank test and 
the multivariate analysis was performed using the Cox regression model. In the final analysis, 
all variables were taken into account to obtain a fully adjusted model. For each variable the 
assumption of proportional hazards was tested. 
In the univariate and multivariate regression analysis, the dependent variables were LOS and 
an adverse event, defined as HF rehospitalisation or death during the follow-up period. The 
independent variables were age, sex, ischemic aetiology, type (de novo versus decompensate 
chronic HF), history of HF hospitalisation in the previous 12 months, obesity, diabetes 
mellitus, ICCU (intensive cardiac care unit) admission, LOS and the following admission 
findings: systolic blood pressure < 100 mmHg, heart rate < 70 beats per minute, serum 
sodium < 135 mmol/L, serum potassium > 4,3 mmol/L, creatinine clearance < 30 ml/min, 
anaemia (haemoglobin lower than 130 g/L in men and 120 g/dL in women), serum B-type 
natriuretic peptide (BNP) > 500 pg/ml, atrial fibrillation (AF),  ventricular ejection fraction 
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(LVEF) < 50%. In the independent variables, the variable aetiology was included instead of 
ACS as precipitating factor, because there was close association between the two variables 
but the aetiology was considered more informative. 
All tests were two-sided and p values less than 0.05 were considered as indicating significant 
differences. Analysis was carried out using the statistical software SPSS 18.0 for Windows. 
Ethics 
The study was carried out according to the principles of the Declaration of Helsinki and 
approved by the hospital ethics committee. 
 
Results 
Baseline characteristics 
From a total of 924 patients admitted to the Cardiology Department over one year, 201 (21%) 
presenting with AHF were enrolled. Patients’ baseline characteristics are summarised in 
Tables 1 and 2. New-onset AHF occurred in more than 50% of cases. Hypertension and 
coronary heart disease (CHD) were the most prevalent underlying diseases, but all the 
cardiovascular risk factors were rather frequent. The most common precipitating factor was 
ACS (63.3% of patients), immediately followed by arrhythmia (14.4% of patients). The most 
frequent clinical presentation was, by far, HF in the context of ACS, followed by chronic 
decompensate heart failure (CDHF) and pulmonary oedema. Interestingly, pulmonary oedema 
was approximately twice as common in patients presenting with ACS than in those with no 
ACS, while CDHF was approximately threefold more frequent in those without ACS than in 
those with ACS. The majority of patients had reduced LVEF on admission. 
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Patients presenting with ACS were significantly younger, more often women and less likely 
to have previous HF history; they had more frequent chronic hypertension and CHD. On the 
other hand, patients without ACS more frequently had valvular disease and dilated 
cardiomyopathy, left ventricular hypertrophy pattern on the ECG, larger left atrium diameter 
and more frequently had AF.   
Hospital course and management 
Echocardiographic examination and BNP were performed in most patients and the majority 
was admitted to the ICCU and submitted to coronary angiography. The overall use of in-
hospital resources was comparable in both ACS and non-ACS groups (Table 3), although a 
higher proportion of ACS patients was admitted to the ICCU. Non-invasive ventilation, IV 
nitrates and diuretics were the basis of therapy and the first two were more often used in ACS 
patients.  
Discharge characteristics 
Comparing admission with discharge, we observed a significant drop in body weight (median 
-3 kg [p25 – p75: -6 – 0]; p<0.001), systolic blood pressure (mean -17.1 mmHg; SD = 29.7; 
p<0.001), heart rate (mean -18.7 bpm; SD = 32.4; p<0.001) and BNP (median -203.5 pg/dl 
[p25 – p75: -850.5 – 74.9]; p<0.001). There was no improvement in creatinine clearance, 
serum sodium and potassium as well as in serum haemoglobin. The rate of prescription of all 
cardiovascular drugs increased from admission to discharge, apart from digoxin and calcium 
channel blockers (Figure 1).  
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Hospital stay and follow-up 
The total length of hospital stay was similar in both groups (median 11 days). In-hospital 
mortality rate was 5.5% and was not significantly different between the two groups. 
Rehospitalisation rate for HF was 20.9% and 23.9% at six and 12 months, respectively.  Most 
readmissions occurred within six weeks after the index event. All-cause mortality was 10.9% 
and 15.9% at six and 12 months, respectively. The variables independently associated with a 
longer LOS were history of HF hospitalisation in the previous year (p=0.040), BNP > 500 
pg/ml (p <0.001) on admission and ICCU admission (p= 0.002) (Table 5S in Supplementary 
data). 
The most important variables predictive of the combined endpoint of rehospitalisation or 
death during the follow-up were history of HF hospitalisation in the previous year (Hazard 
Ratio – HR = 3.177 [1.405 – 7.185]), serum sodium < 135 mmol/L on admission (HR = 1.995 
[1.032 – 3.856]), AF (HR = 1.791 [1.021 – 3.142]) and reduced LVEF (HR = 0.518 [0.268 – 
0.998]) (Table 6S in Supplementary data). 
 
Discussion 
Hospitalisations due to AHF are associated with high mortality and readmission rates, 
representing about 70% of all costs associated with HF (10, 11). They typically occur in 
Internal Medicine or in Cardiology departments and thus most studies include a mixed 
population from both proveniences.  
Clinical information provided by hospital-based studies is crucial to our understanding of the 
contemporary clinical characteristics of AHF, including key prognostic factors and details 
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regarding clinical presentation and medical therapy.  Therefore, we conducted an 
observational hospital-based retrospective study in order to identify the particular 
characteristics of AHF patients exclusively admitted to a Cardiology department.  
Demographics, underlying diseases, type of onset, precipitating factors and clinical 
presentation of AHF  
In our study, the mean age and the gender distribution of the patients were similar to that of 
previous AHF registries in EU and other parts of the world (7, 12) and in the USA (13). 
However, our patients were younger and more often male than those included in an earlier 
Portuguese study performed in Internal Medicine wards (9). Contrary to many previous 
reports, the majority of our patients had reduced LV function, which was perhaps a 
consequence of the high prevalence of ACS in our population. Interestingly a recent Italian 
study (14) also showed that patients admitted to Cardiology departments were younger, more 
often male and more likely to have reduced LVEF than patients in Internal Medicine wards, 
which is coincident with our findings when compared with the mentioned Internal Medicine 
Portuguese study (9). 
Cardiovascular diseases were common amongst our patients, with CHD and hypertension 
being the most frequent, as observed in previous international surveys (7, 12, 13). 
Conventional cardiovascular risk factors, such as obesity, diabetes and dyslipidemia, were 
also very frequent. The prevalence of noncardiovascular comorbidities was similar to that 
observed in previous surveys (12, 13). Chronic pulmonary diseases, anaemia and kidney 
disease were common, with an average creatinine clearance compatible with renal 
insufficiency grade 3. This was similar to the observed in ADHERE (13), reinforcing the 
importance of heart-kidney interaction in AHF.  
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Most patients had new-onset HF, particularly those with an ACS as the precipitating factor. 
The prevalence of de novo AHF was much higher than that in EHFSII (12) and ALARM-HF 
(7, 13).  
ACS was the precipitating factor in nearly two-thirds of the patients. This was almost twofold 
the observed in those reports (7, 12) that included patients of a mixed provenience, from 
Internal Medicine and Cardiology departments.  Arrhythmias were the second most frequent 
precipitating factor and were more common in the non-ACS group. They were mostly of a 
supraventricular origin which is coincident with previous reports of the high frequency of AF 
amongst AHF patients.  
Similarly to EHFSII (12) and ALARM-HF (7) two of the most common clinical presentations 
of AHF in our population were CDHF and pulmonary oedema. 
Diagnostic investigations and treatment  
An ECG, a BNP measurement and an echocardiographic examination were performed in 
nearly all patients on the admission or, alternatively, within the first days of hospitalisation, 
showing good adherence to ESC HF guidelines (3). The high prevalence of ACS explains 
why coronary angiography was performed in more than two-thirds of our patients and why a 
considerably higher percentage of them was admitted to the ICCU, comparatively with the 
observed in EHFSII (12). 
As previously reported by others (7, 12, 13), ventilatory support and intravenous diuretic 
therapy played a central role in the acute management of the patients. Non-invasive 
ventilation was used in the majority of patients. The frequency of administration of 
intravenous nitrates was similar to that previously reported (7, 12, 13) and the use of inotropes 
was nearly half of that registered in those surveys. Approximately one-third of the patients 
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presented with a ST segment elevation myocardial infarction and was submitted to 
percutaneous coronary intervention. This was considerably more frequent than in ADHERE 
(13) and EHFSII (12). 
The observed decrease in body weight, heart rate and BNP at discharge reflected the clinical 
improvement with therapy. Interestingly, blood pressure dropped and no improvement in 
serum creatinine value was observed which demonstrates the limitations of current 
therapeutic options regarding kidney function. 
The prescription of drugs recommended for HF, CHD and hypertension significantly 
increased from admission to discharge. However, the proportion of patients taking 
angiotensin converting-enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) 
was inferior to that in EHFSII (12); a possible explanation for this may be the proportion our 
patients (26.8%) with HF and preserved LVEF, in which these drugs are not formally 
indicated. Conversely, the levels of prescription of beta-blockers (BB), statins, aspirin, 
clopidogrel and nitrates, at discharge, supplanted that of the EHFSII (12), possibly because 
ACS was more frequent in our study than in that survey and those drugs are recommended as 
secondary prophylaxis of ACS. 
Length of stay, outcomes and follow-up of AHF patients 
The overall LOS was 11 days, 2 days longer than that in EHFSII (12) and ALARM-HF (7) 
and almost threefold the reported in ADHERE (13). The median ICCU stay was 6 days, twice 
the reported in EHFSII (12) and ALARM-HF (7). However, in our case, the in-hospital 
mortality rate was 5.5%, which was lower than in EHFSII (12) (in-hospital mortality 6.6%), 
and ALARM-HF (7) (in-hospital mortality 12%).  
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The large scale US surveys ADHERE (13) and OPTIMIZE-HF (15) reported an in-hospital 
mortality of nearly 4%, which is even lower than ours. Nonetheless, this low in-hospital 
mortality, that in part can be a consequence of the very short LOS, was counterbalanced by a 
higher readmission rate and long-term mortality (for instance, OPTIMIZE-HF (15) showed 
90-day rehospitalisation rates and mortality of 30%, and 35%, respectively). One may 
speculate that a longer hospital stay could possibly enable a better patient stabilisation, thus 
reducing long-term morbimortality. 
Our results reinforce the notion that AHF hospitalisations are associated with poor prognosis, 
with more than one-third of the patients dying or being rehospitalised during the subsequent 
year. 
Our patients with new-onset AHF had a more severe clinical presentation, consistently with 
ALARM-HF (7) observation. However, in the long run, patients with CDHF had a higher risk 
of rehospitalisation or death.  
The probability of being rehospitalised was highest during the first weeks after discharge 
from index event and this attests the need of an early medical appointment with the patients 
after discharge, preferably in the setting of a HF management programme (3). 
Predictive factors of a longer LOS and an adverse outcome 
The predictive factors for rehospitalisation after an AHF event remain largely unexplored in 
the literature (16). In our study a baseline BNP value higher than 500 pg/ml was the most 
relevant factor associated with a longer LOS, followed by admission to the ICCU, both 
indicating a more severe initial clinical picture. The history of HF hospitalisations in the 
previous year, a recognized marker of bad prognosis (3), was also associated with a longer 
hospital stay.  Furthermore, it was associated with a threefold increase in the risk of dying or 
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being rehospitalised during the year after discharge. AF also showed a significant association 
with an increased risk of rehospitalisation or death, which is in line with the literature derived 
from the CHF scenario (3, 17-21). 
Other variables also independently associated with a poor long-term outcome were the history 
of previous HF hospitalisation, serum sodium <135 mmol/L on admission and reduced LVEF. 
Together they can help to better select high risk patients for the inclusion into a HF 
management programmes. This is relevant since these programmes can reduce 
rehospitalisations and mortality, are cost-effective and have a ESC class of recommendation I 
with a level of evidence A for HF patients recently hospitalised (3). However, in many 
countries, due to financial constraints and insufficient manpower, it is not possible to admit all 
HF hospitalised patients into a HF management programme.  Thus, identifying the predictors 
of increased vulnerability can help to select the patients most in need of these programmes. 
Patients with versus patients without an ACS as the precipitating factor  
Patients with an ACS typically presented dilated left atria, preserved left ventricular 
dimensions and reduced LVEF on admission.  Left atrial dilation was possibly a consequence 
of the history of hypertension, present in more than 70% of them. A similar percentage of 
those patients had no previous history of HF, explaining why, in the early days of new-onset 
AHF due to an ACS, the left ventricle would not have had enough time to suffer eccentric 
remodelling. 
Patients with an ACS had more frequent and longer ICCU admissions and were more often 
treated with non-invasive ventilation and intra-aortic balloon pump than those without an 
ACS. This suggests a worse initial clinical course in the case of ACS patients as compared 
with those without an ACS. Nonetheless, there was no difference in total hospital LOS, re-
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admission rate, in-hospital mortality and mortality at 6-months or 12-months between the 
groups. 
Study limitations  
This study holds an inherent limitation derived from its retrospective nature. An additional 
drawback has to deal with the possibility of the absence of reporting of death or 
rehospitalisation occurring out of our institution during the follow-up. This could in part be an 
explanation for the observed low long-term rates of rehospitalisation and death.  However, 
due to the existence of consistency in the referral of patients, we believe that probably was not 
a major problem. Furthermore, that cannot explain the low rates of in-hospital mortality we 
also found in our study. 
Conclusion 
Patients admitted to our Cardiology department with AHF more typically presented new-
onset AHF, in the context of an ACS, causing deterioration in left ventricular systolic 
function. They had a longer LOS but a lower 12-months readmission rate and mortality than 
reported in US and EU studies. The independent predictors of rehospitalisation or death were 
HF hospitalisation during previous year, serum sodium < 135 mmol/L on admission, AF and 
reduced LVEF. They can help in the selection of the patients in need of follow-up in a HF 
management programme after discharge. 
 
Conflicts of Interest: none declared.
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Legends 
Figure 1: Oral medications on admission and at discharge for AHF patients. 
McNemmar test for related samples. 
CCB, calcium-channel blocker; MRA, mineralocorticoid receptor antagonist.  
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Tables 
 
Table 1: Underlying diseases, type of onset, precipitating factors and clinical presentation of AHF  
 All patients 
(n=201) 
Patients with ACS 
(n=127) 
Patients without ACS 
(n=74) 
p-value 
 Number (%) 201 127 (63.2) 74 (36.8)  
Age, mean (SD) 69 (13) 71 (11) 66 (14) 0.018 
Male (%)  60.7 55.1 70.3 0.034 
Body mass index (kg/m2),  mean (SD) 26 (4) 26 (4) 26 (4) 0.459 
Cardiovascular diseases (%)     
Chronic Hypertension 66.2 72.4 55.4 0.014 
Coronary artery disease 38.3 44.9 27.0 0.012 
Valvular disease 14.9 5.5 31.1 <0.001 
Dilated cardiomyopathy 7.5 1.6 17.6 <0.001 
Comorbidities (%)     
Diabetes mellitus 37.8 37.0 39.2 0.758 
Obesity  31.3 22.8 45.9 0.001 
Dyslipidemia 51.2 54.3 45.9 0.251 
Tobacco smoking 35.3 37.8 31.1 0.337 
Chronic pulmonary disease 12.4 10.2 16.2 0.215 
Chronic kidney disease 19.4 15.0 27.0 0.037 
Anaemia 35.8 33.1 40.5 0.287 
Active cancer 3.0 3.1 2.7 1.000 
Psychiatric disorder 6.5 8.7 2.7 0.098 
Alcohol abuse 8.5 9.4 6.8 0.508 
 Pacemaker implanted (%) 3.5 1.6 6.8 0.103 
 ICD (%) 3.5 0.0 9.5 0.001 
HF hospitalisation within last 12 months (%) 14.9 8.7 25.7 0.001 
New-onset AHF (%) 53.2 74.0 17.6 <0.001 
Precipitating factors on admission (%)     
ACS 63.2 127 0  
Arrhythmia  14.4 0 39.2  
Drug or dietary noncompliance  8.0 0 21.6  
Valve disease  7.0 0 18.9  
Infection  6.0 0 16.2  
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Clinical presentation (%)     
CDHF  46.8 26.0 82.4 <0.001 
Pulmonary oedema 21.4 26.0 13.5 0.038 
Hypertensive HF  0.5 0.0 1.4 0.368 
Cardiogenic shock  6.0 8.7 1.4 0.035 
Isolated Right HF 0.5 0.0 1.4 0.059 
HF in the context of ACS 63.2 100.0 0.0 <0.001 
p-value for difference between patients presenting with or without ACS.  
Anaemia defined as serum haemoglobin on admission <130 g/L for men and 120 g/L for women; all other 
comorbidities as reported. 
ACS, acute coronary syndrome; AHF, acute heart failure; CDHF, chronic decompensate heart failure; ICD, 
implantable cardioverter/defibrillator; HF, heart failure; SD, standard deviation.  
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Table 2: Physical, laboratory, ECG and echocardiographic findings on admission 
 All patients (n=201) 
Patients with ACS 
(n=127) 
Patients without ACS 
(n=74) 
p-value 
Physical findings, mean (SD)      
SBP (mmHg) 128 (31) 130 (31) 125 (31) 0.350 
DBP (mmHg) 74 (20) 75 (20) 72 (19) 0.191 
Heart rate (beats per minute) 88 (31) 87 (28) 89 (35) 0.705 
 Oxygen Saturation (%), median [p25 – p75] 96 [91 – 98] 95 [90 – 98] 96 [93 – 98] 0.220 
Laboratory values, mean (SD) or median [p25 – p75]      
Serum haemoglobin (g/L) 126 [110 – 139] 125 [111 – 141] 128 [106 – 139] 0.732 
BNP (pg/ml)  841 [313 – 1804] 765 [266 – 1463] 1001 [377 – 2325] 0.111 
Creatinine clearance (ml/min)  57.5 (21.4) 59.3 (21.1) 54.3 (21.7) 0.105 
< 30 ml/min (%) 10.0 8.7 12.2 0.482 
Serum sodium (mmol/L)  138 [135 – 140] 137 [130 – 140] 138 [136 – 140] 0.300 
Serum potassium (mmol/L)  4.1 [3.9 – 4.5] 4.0 [3.7 – 4.5] 4.3 [4.0 – 4.6] 0.025 
ECG (%)     
Atrial Fibrillation  30.8 22.0 45.9 <0.001 
VT  10.4 7.1 16.2 0.041 
Myocardial infarction  66.7 91.3 24.3 <0.001 
LVH  8.5 4.7 14.9 0.013 
Echocardiography     
LVEF (%)     
Preserved  26.8 22.4 34.8  
Moderately reduced 37.1 44.8 23.2 0.010 
Severely reduced  36.1 32.8 42.0  
LA diameter (mm), median [p25 – p75] 43 [40 – 48] 42 [39 – 45] 47 [43 – 55] <0.001 
EDLV diameter (mm), median [p25 – p75] 52 [48 – 59] 51 [47 – 55] 58 [50 – 64] <0.001 
p-value for difference between patients presenting with or without ACS.  
DBP, diastolic blood pressure; EDLV, end diastolic left ventricular; LA, left atrial; LVEF, left ventricular 
ejection fraction; LVH, left ventricular hypertrophy; SBP, systolic blood pressure; SD, standard deviation; VT, 
ventricular tachyarrhythmia. 
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Table 3: Diagnostic investigations, procedures and acute cardiac care 
Procedure/Treatment (% performed) All patients (n=201) 
Patients with ACS 
(n=127) 
Patients without ACS 
(n=74) 
p-value 
Admission to ICCU 77.1 91.3 52.7 <0.001 
ECG 98.5 100.0 95.9 0.049 
Echocardiography 96.5 98.4 93.2 0.103 
BNP 89.6 91.3 86.5 0.340 
Cardiac scintigraphy  10.4 13.4 5.4 0.074 
Coronary angiography  69.7 85.3 45.9 <0.001 
Pulmonary artery catheter  5.5 4.7 6.8 0.188 
     
Percutaneous coronary intervention  32.8 48.8 5.4 <0.001 
 Invasive ventilation 8.5 8.7 8.1 0.892 
Non-invasive ventilation 63.5 69.3 53.4 0.025 
Intravenous diuretics 62.5 58.3 59.9 0.103 
Intravenous nitrates 34.5 42.5 20.5 0.002 
Intravenous inotropes  13.9 13.4 14.9 0.770 
Intra-aortic balloon pump 3.5 5.5 0.0 0.048 
Dialysis  2.5 2.4 2.7 1.000 
Pacemaker  5.0 1.6 10.8 0.004 
ICD 6.5 4.7 9.5 0.188 
p-value for difference between patients presenting with or without ACS.  
ACS, acute coronary syndrome; BNP, B-type natriuretic peptide; ICCU, intensive cardiac care unit; ICD, 
implantable cardioverter/defibrillator. 
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Table 4: Length of stay, outcomes and follow-up  
 All patients (n=201) 
Patients with ACS 
(n=127) 
Patients without ACS 
(n=74) 
p-
value 
Length of stay (days), median [p25 – p75]     
Total 11 [7 – 16] 11 [7 – 16] 11 [6 – 18] 0.864 
ICCU  6 [4;12] 3 [2;5] 1 [0;4] <0.001 
CW 6 [4;12] 6 [4;11] 7 [4;14] 0.131 
 In-hospital mortality (%) 5.5 3.9 8.1 0.210 
 
Follow-up  
    
 Hospitalisation within 6 months (%)   20.9 18.9 24.3 0.361 
 Hospitalisation within 12 months (%) 23.9 22.8 25.7 0.649 
 Department of first readmission (%)     
Cardiology department 27.1 24.1 31.6  
Internal medicine department 66.7 69.0 63.2 0.843 
ICU of emergency department 6.3 6.9 5.3 
 Months after index admission, median [p25 – p75] 1.5 [0.8 – 4.5] 2.0 [1.0 – 5.0] 1.5 [0.5 – 4.0] 0.586 
 Rehospitalisations *, median [p25 – p75] 1 [1 – 2] 1 [1 – 2] 1 [1- 2] 0.605 
 Mortality at 6 months (%)     
 Heart failure 7.5 4.7 12.2 0.053 
 All cause 10.9 8.7 14.9 0.174 
  Mortality at 12 months (%)     
 Heart failure 10.9 8.7 14.9 0.174 
 All cause  15.9 14.2 18.9 0.375 
 Adverse endpoint ** 34.8 31.5 40.5 0.301 
* Number of heart failure rehospitalisations during the year after index admission. 
** Adverse endpoint defined as death or heart failure rehospitalisation during the total follow-up period. 
p-value for difference between patients presenting with or without ACS.  
CW, cardiology ward; ICCU, intensive cardiac care unit; ICU, intensive care unit. 
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Figures  
Figure 1 
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Supplementary data 
Table 5S: Variables associated with death or rehospitalisation within one year after index admission 
Variables Crude HR* [CI 95%] p-value Adjusted HR* [CI 95%] p-value 
Age (≤65 versus >65)  2,041 [1,151 – 3,619] 0,015 1,360 [0,674 – 2,742] 0,390 
Sex (male versus female) 1,192 [0,729– 1,947] 0,484 1,175 [0,618 – 2,234] 0,623 
Aetiology (ischemic versus nonischemic) 0,860 [0,518 – 1,427] 0,560 1,515 [0,718 – 0,3200] 0,276 
De novo versus decompensate 1,697 [1,052 – 2,738] 0,030 1,228 [0,615 – 2,451] 0,561 
HF hospitalisation in the previous year  2,370 [1,369 – 4,102] 0,002 3,177 [1,405 – 7,185] 0,006 
Diabetes mellitus 1,590 [0,991 – 2,553] 0,055 1,847 [0,969 – 3,519] 0,062 
Obesity (BMI>30 kg/m2) 1,354 [0,832 – 2,205] 0,222 1,105 [0,571 – 2,139] 0,767 
Admission assessment  
SBP <100 mmHg 1,472 [0,851 – 2,545] 0,167 1,126 [0,577 – 2,198] 0,729 
Heart rate <70 bpm 0,735 [0,394 – 1,373] 0,335 0,876 [0,417 – 1,842] 0,727 
Anaemia 2,189 [1,364 – 3,512] 0,001 1,112 [0,574 – 2,152] 0,754 
BNP >500 pg/ml 1,592 [0,907 – 2,791] 0,105 1,317 [0,682 – 2,542] 0,412 
CrCl <30 ml/min 2,260 [1,155 – 4,419] 0,017 0,763 [0,256 – 2,276] 0,628 
Na <135 mmol/L 1,899 [1,128 – 3,197] 0,016 1,995 [1,032 – 3,856] 0,040 
K >4,3 mmol/L 0,962 [0,595 – 1,556] 0,876 0,609 [0,330 – 1,123] 0,112 
AF 1,820 [1,130 – 2,931] 0,014 1,791 [1,021 – 3,142] 0,042 
LVEF <50% 0,703 [0,422 – 1,170] 0,175 0,518 [0,268 – 0,998] 0,049 
ICCU admission 1,215 [0,710 – 2,080] 0,478 0,833 [0,407- 1,708] 0,619 
Length of stay 1,010 [0,993 – 1,027] 0,243 0,995 [0,960 – 1,030] 0,757 
* Crude HR was calculated using univariate Cox regression models. Adjusted HR was calculated using 
multivariate weighted Cox regression models. Fully adjusted estimates took into account all 18 variables. 
Anaemia defined as serum haemoglobin on admission <130 g/L for men and 120 g/L for women. 
AF, atrial fibrillation; BNP, B-type natriuretic peptide; BMI, body mass index; CrCl, creatinine clearance; HF, 
Heart failure; HR, hazard ratio; ICCU, intensive cardiac care unit; LVEF, left ventricular ejection fraction; SBP, 
systolic blood pressure. 
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Table 6S: Variables associated with a longer length of stay 
Variables 
Crude mean difference* 
[95% CI] 
p-value 
Adjusted mean difference* 
[95% CI] 
p-value 
Age (≤65 versus >65)  0,056 [-0,156 – 0,269] 0,602 0,160 [-0,036 – 0,355] 0,110 
Sex (male versus female) 0,010 [-0,194 – 0,215] 0,922 -0,041 [-0,234 – 0,152] 0,676 
Aetiology (ischemic versus nonischemic) -0,141 [-0,360 – 0,077] 0,204 -0,194 [-0,417 – 0,028] 0,087 
Decompensate versus de novo 0,245 [0,048 – 0,442] 0,015 0,140 [-0,074 – 0,354] 0,198 
HF hospitalisation in the previous year 0,412 [0,138 – 0,687] 0,003 0,287 [0,013 – 0,560] 0,040 
Diabetes mellitus 0,011 [-0,195 – 0,217] 0,915 0,011 [-0,179 – 0,201] 0,909 
Obesity (BMI>30 kg/m2) -0,059 [-0,275 – 0,156] 0,587 -0,234 [-0,433 – -0,035] 0,021 
Admission 
assessment  
SBP <100 mmHg 0,071 [-0,187 – 0,328] 0,590 -0,007 [-0,224 – 0,209] 0,946 
Heart rate <70 bpm -0,130 [-0,373 – 0,112] 0,291 -0,026 [-0,240 – 0,188] 0,810 
Anaemia 0,180 [-0,027 – 0,386] 0,088 0,050 [-0,158 – 0,258] 0,638 
BNP >500 pg/ml 0,518 [0,317 – 0,719] <0,001 0,368 [0,174 – 0,563] <0,001 
CrCl <30 ml/min 0,390 [0,045 – 0,736] 0,027 0,233 [-0,113 – 0,579] 0,186 
Na <135 mmol/L 0,065 [-0,185 – 0,315] 0,610 -0,031 [-0,250 – 0,188] 0,784 
K >4,3 mmol/L -0,105 [-0,306 – 0,096] 0,305 -0,063 [-0,242 – 0,116] 0,490 
AF 0,101 [-0,115 – 0,317] 0,356 0,069 [-0,122 – 0,260] 0,478 
LVEF <50% 0,066 [0,149 – 0,281] 0,546 0,070 [0,137 – 0,276] 0,507 
ICCU  admission  0,272 [0,037 – 0,507] 0,023 0,362 [0,131 – 0,593] 0,002 
* Crude mean differences were calculated using univariate linear regression models. Adjusted mean differences 
were calculated using multivariate weighted linear regression models. Fully adjusted estimates took into account 
all 17 variables. 
Anaemia defined as serum haemoglobin on admission <130 g/L for men and 120 g/L for women. 
95% CI, 95% confidence interval; AF, atrial fibrillation; BMI, body mass index; BNP, B-type natriuretic 
peptide; CrCl, creatinine clearance; HF, Heart failure; ICCU, intensive cardiac care unit; LVEF, left ventricular 
ejection fraction; SBP, systolic blood pressure. 
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